TENUATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TENUATE (TENUATE).
Tenuate (diethylpropion) is a sympathomimetic amine that acts as an appetite suppressant. It stimulates the release of norepinephrine and to a lesser extent dopamine from presynaptic nerve terminals in the hypothalamus, increasing satiety.
| Metabolism | Extensively metabolized in the liver via N-dealkylation to active metabolites (ethylaminopropiophenone and diethylaminopropiophenone). Enzymes involved include CYP3A4 and CYP2D6. |
| Excretion | Renal (90% as metabolites, ~10% unchanged); minor biliary/fecal (<10%) |
| Half-life | 4-6 hours (terminal); clinical context: short half-life supports multiple daily dosing |
| Protein binding | ~92% (primarily albumin) |
| Volume of Distribution | ~4 L/kg (extensive tissue distribution, including CNS) |
| Bioavailability | Oral: ~60-70% (first-pass metabolism) |
| Onset of Action | Oral: 30-60 minutes; IV: immediate; IM: 15-30 minutes |
| Duration of Action | 4-6 hours (oral); clinical notes: anorectic effect lasts 4-6 hours, requiring multiple daily doses |
25 mg orally three times daily before meals, or 75 mg extended-release orally once daily in the morning.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment (GFR <30 mL/min) due to potential accumulation. |
| Liver impairment | Contraindicated in Child-Pugh Class C; use with caution in Class A and B, consider dose reduction. |
| Pediatric use | Not recommended for children under 16 years of age. |
| Geriatric use | Initial dose at 12.5 mg twice daily; titrate slowly due to increased sensitivity and risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TENUATE (TENUATE).
| Breastfeeding | Excreted in human milk; M/P ratio not determined. Potential for adverse effects in nursing infants (e.g., irritability, poor weight gain). Use caution; decision to discontinue nursing or drug based on importance to mother. |
| Teratogenic Risk | First trimester: Limited human data, but animal studies suggest increased risk of cardiovascular and neural tube defects. Second and third trimesters: Associated with reduced fetal growth and neonatal withdrawal symptoms (tremors, hypertonia, feeding difficulties). Avoid use unless clearly needed. |
■ FDA Black Box Warning
There is no FDA boxed warning for Tenuate.
| Serious Effects |
["Hypersensitivity to diethylpropion or other sympathomimetic amines.","Advanced arteriosclerosis, cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma.","History of drug abuse, agitated states.","Concurrent use (or within 14 days of discontinuing) MAO inhibitors (hypertensive crisis risk)."]
| Precautions | ["Primary pulmonary hypertension: rare but serious condition associated with use.","Cardiac valvulopathy: risk increases with prolonged use or combination with other serotonergic drugs.","Tachyphylaxis: tolerance to anorectic effects may develop within a few weeks.","Psychiatric effects: may exacerbate psychiatric disorders, particularly in patients with history of substance abuse.","Seizures: risk increased in patients with epilepsy or history of seizures."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, heart rate, and weight. Assess fetal growth via ultrasound if used long-term. Monitor neonate for withdrawal symptoms if used near term. |
| Fertility Effects | Not formally studied in humans. In animal studies, no significant impact on fertility reported. Potential for menstrual irregularities in women due to CNS stimulation. |